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Summary
Objective: The effects of inﬂammation on bone development from mesenchymal stem cells (MSC) are unclear due to the difﬁculty in isolating
MSC. The aim of this study was to develop a MSC isolation method and to determine the in vitro effects of interleukin-1b (IL-1b) and tumor
necrosis factor a (TNFa) on their osteogenic differentiation.
Methods: Murine MSC were isolated from the limbs of C57/Bl6 mice through collagenase digestion of bone and enriched as the Stem cell
antigen (Sca-1)þ CD31 CD45 population, using lineage immunodepletion, followed by ﬂuorescence-activated cell sorting (FACS). They
were differentiated along the osteoblast linage in the presence or absence of IL-1b and TNFa. Mineralization was measured as was the ex-
pression of a number of osteogenic genes by quantitative polymerase chain reaction (PCR).
Results: We show that osteogenic differentiation from the MSC population is suppressed by IL-1b and TNFa. In addition to suppression of
bone mineralization, both cytokines inhibited the differentiation-associated increases in alkaline phosphatase (ALP) activity and the gene
expression for ALP, a1(I) procollagen, runt-related transcription factor 2 (Runx2) and osterix. However, only TNFa inhibited osteonectin
and osteopontin mRNA expression and only IL-1b reduced cell proliferation.
Conclusions: The convenient isolation technique enables the easy generation of sufﬁcient MSC to permit the molecular analysis of their dif-
ferentiation. We were thus able to show that the proinﬂammatory cytokines, IL-1b and TNFa, can compromise bone development from this
primary MSC population, although with some signiﬁcant differences. The potential involvement of speciﬁc inﬂammatory mediators needs to
be taken into account if optimal bone repair and presumably that of other tissues are to be achieved with MSC.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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forming unit ﬁbroblasts (CFU-F) in bone marrow stromal
populations which were capable of forming colonies of cells
morphologically similar to ﬁbroblasts. These mesenchymal
stem cells (MSC) were rapidly adherent, non-phagocytic,
clonogenic, capable of extended proliferation in vitro2 and
had tri-lineage (bone/fat/cartilage) potential3. MSC have
generated a great deal of recent interest for tissue engineer-
ing and therapeutic applications because of their multipo-
tentiality and relative ease of isolation from many
tissues4e7.
Our current understanding of how MSC behave in various
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735niches is a rapidly expanding ﬁeld of study7 but MSC
interaction within a disease microenvironment is poorly un-
derstood. Prior studies have investigated the in vitro effects
of cytokines, including those with proinﬂammatory activity,
on mesenchymal progenitor populations to determine
what inﬂuence an inﬂammatory reaction might have, for ex-
ample, on bone formation. This question is of potential sig-
niﬁcance since tissue regeneration is often needed in areas
of the body where there is signiﬁcant damage and hence an
inﬂammatory reaction. Much of this prior in vitro analysis
has utilized immortalized cell lines or quite heterogeneous
populations of bone marrow stromal cells isolated by adher-
ence to plastic8e10. As an example of a problem which can
arise from the use of cell lines, a number of studies have
suggested that MSC populations from normal tissue exhibit
anti-proliferative, immunomodulatory and anti-inﬂammatory
effects which have not been observed with precursor cell
lines11,12.
Stem cell antigen (Sca-1), a member of the Ly-6 multi-
gene family, has been used, in combination with other line-
age-speciﬁc antigens, for the puriﬁcation of murine
MSC13e15. Such isolated cells can subsequently be cul-
tured and differentiated into osteoblasts, chondrocytes
and adipocytes in vitro16. We have used an adaption of
this approach to isolate and expand a highly enriched pop-
ulation of murine MSC and then compared the effects of the
736 D. C. Lacey et al.: Implications for bone repair during inﬂammationkey proinﬂammatory cytokines, interleukin-1b (IL-1b) and
tumor necrosis factor a (TNFa), on their osteogenic capacity.
We report signiﬁcant effects of these cytokines in suppress-
ing osteoblast development, both at the differentiation and
proliferation levels, although with some speciﬁcity in the re-
sponses to a particular cytokine.
Materials and methods
All animal experiments were preformed in accordance with Australian law
and under the approval of the ethics committee of TheUniversity of Melbourne.MSC ISOLATION AND CULTUREThe isolation protocol for murine MSC was adapted from Short et al. and
Wong et al.13,17 Brieﬂy, using this protocol femur, tibia and iliac crest were
removed from male C57Bl/6 mice aged 4e6 weeks, purchased from Monash
University (Clayton, Australia). Following marrow release (mortar and pes-
tle), the bones were washed with phosphate buffered saline (PBS), supple-
mented with 2% fetal bovine serum (FBS), until all the marrow was removed.
Cells were released from bone following collagenase digestion from ﬁnely
chopped bone and then ﬁltration to remove fragments. The stromal precursor
cells were isolated by magnetic bead depletion of lineage-speciﬁc popula-
tions using antibodies (Pharmingen) against the following surface markers:
CD3, CD4, CD5, CD8, Mac-1, B220 and Gr-1; the remaining cells were
sorted as Sca-1þ CD31 CD45 cells using a ﬂuorescence-activated cell
sorting (FACS) Vantage SE ﬂow cytometer (BD Bioscience). In order to in-
crease numbers prior to osteoblast differentiation, the cells were cultured
for approximately 14 days in a-MEM supplemented with 20% FBS (Hyclone)
and usually passaged 2e4 times. Sca-1þ CD31 CD45 cells were also iso-
lated from bone marrow in a similar manner. Photographs of MSC were
taken with an AxioCam MRc5 camera on a Axiovert 25 microscope (Zeiss)
at 100 magniﬁcation.Fig. 1. MSC isolation, expansion and differentiation. (A) MSC were isola
Sca-1þ CD31 CD45 cells from murine bone. A representative proﬁle a
expanded in vitro in normal medium. The cultures of the rapidly growing p
cells; (ii) after 3 days; (iii) after 10 days; and (iv) after 12 days. Photograph
MSC were differentiated for 7 days in OM or 14 days in either chondrogen
the genes associated with (i) osteogenesis, namely ALP and Col1a1, (ii)
genesis, namely PPAR gamma and adipisin, was measured by real-tim
Representative examples of three separate experOSTEOBLAST DIFFERENTIATION ASSAYExpanded MSC were used between passage 2 and 4 (see above). Trip-
licate cultures of 1 104 cells per well were seeded onto a 12 well plate over-
night at 37C in 5% O2/10% CO2. The cells were then cultured in osteogenic
medium (OM) (i.e., normal medium (see above) but supplemented with dexa-
methasone (10 nM), ascorbate-2-phosphate (0.1 mM) and b-glycerol-phos-
phate (1 M) (Sigma)) and cultured for 4 or 6 weeks at 37C in 5% O2/10%
CO2, with the medium being replaced every 3e4 days
18,19. Cells were
also treated with murine IL-1b (0.001e1 ng/ml) or murine TNFa
(0.01e10 ng/ml) (R&D Systems) throughout the differentiation assay, and
fresh cytokines added at every medium change.
Osteoblast differentiationwas determinedbyalkalinephosphatase (ALP)ac-
tivity and Von Kossa staining. ALP activity was determined as described else-
where20. In brief, cultures were washed with PBS and ﬁxed in 10% buffered
formalin for 10 min, stained for 30 min with fresh, 0.22 mm-ﬁltered, 0.1 M
TriseHCl, pH8.3, containing0.6 mg/ml redviolet LBsalt and0.1 mg/mlnaphthol
ASMX-PO4 dissolved in N,N-dimethylformamide (Sigma). Plates were washed
and pictures taken by scanning on a GS-710 scanner (Bio-Rad). For the Von
Kossa staining, cells were covered with 5% aqueous silver nitrate and placed
under UV for 30 min. Cells were washed in water and covered with 5% sodium
thiosulphate for 5 min, before washing with water and scanning the plate.CHONDROCYTE DIFFERENTIATION ASSAYExpanded MSC were used between passage 2 and 4. Cells were removed
from the plate with 0.05% w/v trypsin-EDTA, washed with PBS before being
resuspended in serum-deprived medium (a-MEM with 1% ﬁnal w/v of bovine
serum albumin (BSA), supplemented with transferring (100 mg/ml), insulin
(10 mg/ml) and low-density lipoprotein (LDL) (20 mg/ml)). Micro-mass cultures
were established by pipetting 5 105 cells in 45 ml into a 12 well plate and al-
lowing the cells to adhere to the plate for 1 h before adding 1 mL serum-de-
prived medium with addition of the growth factors transforming growth factor
(TGF)-b3 (10 ng/ml), bonemorphogenic protein (BMP)-6 (10 ng/ml) and plate-
let-derived growth factor (PDGF)-BB (50 ng/ml)20e23. Medium was replaced
on the micro-mass every 3 days and fresh growth factors were added withted by ﬂow cytometry using positive selection in the ﬁnal stage as
t this stage is provided; cells in R1 were collected. (B) MSC were
opulation can be seen at various stages: (i) initial plating as single
s were taken at 100 magniﬁcation on an Axiovert microscope. (C)
ic or adipogenic conditions and compared to ND. The expression of
chondrogenesis, namely Col2a and aggrecan (Agc), and (iii) adipo-
e PCR. The expression levels were normalized to those for 18S.
iments; bars represent mean values S.E.M.
Table I
Sca-1þ CD45 CD31 sorted cell counts from digested bone and
bone marrow
Source of cells Starting cell
no. (106)
Sca-1þ CD45 CD31
cells sorted
Bone 54 6 4900 690
Bone marrow 140 20 27 6
737Osteoarthritis and Cartilage Vol. 17, No. 6each medium change. Assays were run for 2 weeks and then the pellets were
washed twice in PBS at which point RNA was isolated.ADIPOGENIC DIFFERENTIATION ASSAYExpanded MSC were used between passage 2 and 4. Triplicate cultures
of 1 104 cells per well were seeded onto a 12 well plate overnight at 37C
in 5% O2/10% CO2. The medium was then replaced on the cells to induce
differentiation as follows. Initial inductive medium was added for the ﬁrst
3e4 days of the assay, consisting of Dulbecco’s modiﬁed essential medium
(DMEM) supplemented with 10% v/v horse serum (Gibco) and hydrocorti-
sone (108 M), indomethacin (60 mM) and 1-isobutyl-3-methylxanthine
(IBMX) (500 mM)24,25. Medium was replaced after the inductive period with
DMEMþ 10% horse serum for the remainder of the assay, (typically 2
weeks) at which point RNA was isolated.RNA COLLECTION ANDQ-POLYMERASE CHAIN REACTION (PCR)Total RNA was isolated from cytokine-treated osteoblast differentiation
cultures (day 7), chondrocyte differentiation cultures (day 14) or adipocyte
differentiation cultures (day 14) using RNeasy according to the manufacturer’s
instructions (Qiagen). Approximately 2 mg total RNAwas converted to cDNA us-
ingOmniscriptRTkit (Qiagen) according to themanufacturer’s instructions.PCR
wasperformedonanABI7900HT real-timePCRmachine (AppliedBiosystems).
PCR reactions were performed in a total volume of 10 ml in 1 Taqman master
mix (AppliedBiosystems) with 4 ml cDNA, 1 ml 18S primer, or 1 ml of the followingFig. 2. Effect of IL-1b and TNFa on mineralization and ALP activity in diff
culture plates and grown in OM and treated with IL-1b (0.001e1 ng/ml) or
position (Von Kossa staining) or (B) ALP activity. Repreprimer sets from Applied Biosystems: runt-related transcription factor 2 (Runx2)
(Assay ID Mm00501578_m1, reference sequence NM_009820.3), Osterix
(Assay ID Mm00504574_m1, reference sequence mCT52977.2), ALP (Assay
ID Mm00475831_m1, reference sequence NM_007431.2), a1(I) procollagen
(Col1a1) (Assay ID Mm0801666_g1, reference sequence NM_007742.2),
osteopontin (Opn) (Assay ID Mm00436767_m1, sequence reference
NM_009263.1), osteonectin (SPARC) (Assay ID Mm00486332_m1, sequence
reference NM_009242.1), collagen type II alpha 1 (Col2a1) (Assay ID
Mm00491889_m1, sequence reference NM_031163.2) and aggrecan (Agc)
(Assay ID Mm00545794_m1, sequence reference NM_007424.2).
Alternatively, PCR reactions for adipocyte genes were performed in a total
volume of 10 ml in 1 SYBR green master mix (Applied Biosystems) with 4 ml
cDNA and 1 ml of the following primer sets (Geneworks, SA, Australia): adip-
sin, forward 50-AGACCCCTACCCTTGCAATACG-30, reverse 50-TGTTACCA
TTTGTGATGTTTTCGATC-30; peroxisome proliferator-activated receptor
(PPAR) gamma, forward 50-TTTTCCGAAGAACCATCCGAT-30, reverse 50-
ACAAATGGTGATTTGTCCGTTG-30. Gene expression was quantitated rel-
ative to 18S using an ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster City, CA, USA). Each cDNA sample was detected in
experimental triplicate. Negative control reactions were cycled alongside
test samples to ensure the absence of contaminating genomic DNA. Data
were analyzed using the ABI Prism software, and expression was deter-
mined relative to 18S mRNA. Transcript abundance ( gene/18S ) and SD
were calculated as recommended by Applied Biosystems. The values for
non-differentiated cells (ND) (Fig. 1) or cells treated only with OM (Fig. 3)
were set as 1.CELL PROLIFERATIONExpanded MSC were seeded onto 12 well plates in triplicate cultures at
1 104 cells per well overnight at 37C in 5% O2/10% CO2. They were cul-
tured as for the osteoblast differentiation assay (see above) for 7 days. Cells
were removed from the plates with trypsin and viable cell numbers counted
by trypan blue exclusion.STATISTICAL ANALYSISStatistical analysis was performed using Students’ t test; P 0.05 was
considered signiﬁcant.erentiating MSC. Expanded MSC were seeded onto 12 well tissue
TNFa (0.01e10 ng/ml) for 4 weeks and stained for (A) calcium de-
sentative example of three separate experiments.
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Fig. 3. Effect of IL-1b and TNFb on osteoblast lineage gene expression in differentiating MSC. Expanded MSC were seeded onto 10 cm tissue
culture plates and grown in OM and treated with IL-1b (1 ng/ml) or TNFa (10 ng/ml) for 7 days at which time RNA was isolated and the ex-
pression of the osteoblast lineage genes, (A) ALP, (B) Col1a1, (C) osteonectin, (D) osteopontin, (E) Runx2 and (F) osterix, measured by real-
time PCR. The expression levels were normalized to those for 18S. Values are presented relative to the control value in OM. Bars represent
mean values S.E.M. (n¼ 5). *P< 0.05.
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PRECURSOR CELLSThe isolation of murine stromal precursor cells is particu-
larly challenging because of, for example, the extremely low
incidence of CFU-F (typically in the range of
0.001e0.0001% in bone marrow3,26), the relative lack of
cell surface markers to aid in their isolation and the difﬁculties
in propagating them in culture17. Studies in one of our labora-
tories have shown that the major reservoir of CFU-F in the
adult mouse is the surrounding bone tissue and not the mar-
row which has allowed the isolation of a highly enriched pop-
ulation of stromal progenitors based on the composite
phenotype Sca-1þ Lin CD31 CD45 that has a plating ef-
ﬁciency for CFU-F of approximately 30%17. As an illustration
of the ﬁnal stage of isolation, the FACS proﬁle of the sorted
Sca-1þ CD31 CD45 population (Materials and methods)is provided in Fig. 1(A); the cells represent approximately
0.01% of the original digested bone cells with an absolute
yield between 3000 and 5000 cells from six mice. As a popu-
lation and at the clonal level, these cells exhibit considerable
proliferative potential in vitro [Fig. 1(B)] (>50 population dou-
blings) whilemaintaining their tri-lineage differentiation (bone/
fat/cartilage) capacity (see below). We refer for convenience
to this enriched population as MSC throughout the paper.
That this Sca-1þCD31CD45 population is more abundant
in the bone (1 in 12,000) than in the bone marrow (1 in 6 mil-
lion) can be seen in Table I. In order to conﬁrm and illustrate
that the expanded Sca-1þ CD31 CD45 population used in
this paper maintained tri-lineage potential, osteoblast, chon-
drocyte and adipocytemarker geneswasmeasured following
differentiation with appropriate stimuli [Fig. 1(C)]. When these
cells were differentiated down a particular lineage there was
an increase in the expression of genes associatedwith osteo-
genesis (ALP and a1(I) procollagen (Col1a1))19,
Fig. 4. Effect of IL-1b and TNFb on chondrocyte and adipocyte lineage gene expression in differentiating MSC. Expanded MSC were differ-
entiated in either chondrogenic (Chon) or adipogenic (Adipo) conditions and treated with IL-1b (1 ng/ml) or TNFa (10 ng/ml) for 14 days at
which time RNA was isolated and the expression of lineage-speciﬁc genes, (A) Col2a, (B) aggrecan (Agc), (C) PPAR gamma, and (D) adipisin,
measured by real-time PCR. The expression levels were normalized to those for 18S. Values are presented relative to the control values. Bars
represent mean values S.E.M. (n¼ 3). *P< 0.05.
739Osteoarthritis and Cartilage Vol. 17, No. 6chondrogenesis (collagen type IIa (Col2a) and aggrecan)19,
and adipogenesis (PPAR gamma and adipisin)25, respec-
tively. The comparator for each treatment is undifferentiated
cells.EFFECT OF IL-1 AND TNFa ON OSTEOGENESISMineralization and ALP activity
Osteogenic differentiation of the MSC was carried out, in
the absence and presence of IL-1b or TNFa, for 4 weeks af-
ter which time mineralization (Von Kossa staining) and ALP
activity were measured. MSC cultured in OM alone (Mate-
rials and methods) demonstrated signiﬁcant mineralization
[Fig. 2(A)] and had high ALP activity [Fig. 2(B)] indicating
extensive differentiation along the osteoblast lineage; treat-
ment of the MSC with either IL-1b or TNFa dose depen-
dently inhibited this differentiation [Fig. 2(A and B)] with
the former being more potent on a molar basis.
Osteoblast lineage gene expression
ALP and Col1a1 are widely used markers of osteoblasts,
the latter being the most abundant protein in bone19.
Figure 3(A and B) shows that both IL-1b and TNFa sup-
press ALP mRNA expression and that for Col1a1. The skel-
etal speciﬁc matrix protein, osteonectin, and osteopontin
are also widely used markers of osteoblasts. Figure 3(C
and D) shows that TNFa suppressed mRNA expression
for both but, interestingly, IL-1b did not.
The expression of the transcription factors, Runx2 and os-
terix, has been shown to be necessary for osteoblast differ-
entiation at a relatively early stage17. In order to begin to
explore the mechanism for the effect of the cytokines on os-
teogenesis in our system, the levels of gene expression forthese key transcription factors were monitored. As seen in
Fig. 3(E and F), both IL-1b and TNFa reducedmRNA expres-
sion for both Runx2 and osterix; IL-1b and TNFa were active
even at 0.1 ng/ml and 1 ng/ml, respectively (data not shown).
As a check on how general the suppressive effects of IL-
1b and TNFa are on the differentiation of other cell types
from MSC, chondrogenic and adipogenic differentiation
was carried out, in the absence and presence of IL-1b or
TNFa, for 2 weeks and gene expression again measured.
Figure 4(A and B) shows that both IL-1b and TNFa sup-
press Col2a and aggrecan (Agc) mRNA expression as
markers of chondrogenesis; likewise both inﬂammatory cy-
tokines also suppress mRNA expression of the adipocyte
markers, PPAR gamma and adipsin [Fig. 4(C and D)].
MSC proliferation
A key element in tissue development is the proliferation
from mesenchymal precursors. Alterations in the differenti-
ation along a cell lineage may or may not be accompanied
by changes in the rate of cell proliferation and both IL-1b
and TNFa can inﬂuence this parameter in other cell
types27,28. We therefore monitored the effects of these cyto-
kines on cell number during MSC osteogenesis. IL-1b treat-
ment inhibited MSC proliferation in a dose dependent
manner down to 0.01 ng/ml [Fig. 5(A)]; interestingly, in con-
trast, TNFa, even at a concentration of 10 ng/ml, had no
effect [Fig. 5(B)].
Discussion
MSC have been isolated from many different tissues us-
ing numerous techniques; here we have isolated MSC from
cortical bone which is different from many reported studies.
The most resent study by Sorrentino et al. used human
Fig. 5. Effect of IL-1b and TNFa on the proliferation of differentiating
MSC. Expanded MSC were seeded onto 12 well tissue culture
plates and grown in triplicate cultures in OM and treated with (A)
IL-1b (0.001e1 ng/ml) or (B) TNFa (0.01e10 ng/ml) for 7 days.
Cells were removed and viable cells counted by trypan blue exclu-
sion. Data from a representative experiment are shown which was
repeated three times. Bars represent mean values S.E.M. (n¼ 3).
*P< 0.01.
740 D. C. Lacey et al.: Implications for bone repair during inﬂammationbone marrow cells and CD146 as a marker of MSC29. Their
method varies from ours since they ﬁrst immuno-depleted
human bone marrow using anti-CD3, CD14, CD19, CD38,
CD66b, and CD34 antibodies before culturing the enriched
cells for 2 weeks, at which point CD146þ cells were used in
experiments. In comparison we have used mouse cells from
cortical bone as opposed to bone marrow; in addition, we
have used a wider selection of immuno-depleting antibodies
and positively selected Sca-1þ cells before culturing our
enriched population.
The aim of our study was to determine how a highly de-
ﬁned MSC population might behave in an inﬂammatory en-
vironment and therefore to determine the feasibility of using
MSC to repair tissue in an inﬂammatory microenvironment.
In general, even though the receptors for IL-1b and TNFa
are quite different they can still activate some common in-
tracellular pathways leading to similar but not identical cel-
lular responses30. Prior studies examining the effects of
IL-1b and TNFa on osteogenesis have usually not directly
compared these proinﬂammatory cytokines and have usu-
ally used stem cell lines or heterogeneous populations of
bone marrow stromal cells. We used primary cultures of
an enriched, bone-derived population of highly proliferative
Sca-1þ CD31 CD45 progenitor cells and have shown for
the ﬁrst time with such cells that both IL-1b and TNFa caninhibit their osteogenesis, albeit with some differences.
Both cytokines suppressed mineralization, ALP activity
and mRNA expression for Col1a1, Runx2 and osterix,
with IL-1b being generally effective at a lower concentration
than TNFa. However, IL-1b, unlike TNFa, could not prevent
osteonectin and osteopontin gene expression during differ-
entiation; in contrast, IL-1b, but not TNFa, reduced the num-
ber of osteoblast-like cells able to be generated by
proliferation in the OM. Thus the effects of IL-1b and
TNFa on osteogenesis from the progenitor cells need to
be considered individually and our data indicate that they
are likely therefore to inﬂuence osteogenesis differently at
sites of inﬂammation (see below). As the cell population
used is an enriched population, the possibility that the differ-
ences seen are due to alternate effects on different cell
types cannot be excluded.
There are data suggesting that Runx2 is upstream of
osterix and that this pathway governs osteoblast differentia-
tion1. Our data showing that the suppressive effects of IL-1b
and TNFa on the gene expression of both transcription
factors are consistent with a link between them and with
the suppressive effects of TNFa on their gene transcription
in calvaria and in cell lines8,10,31e35. The discordant effect of
the cytokines on osteopontin gene expression is surprising
given the evidence from Kim et al. where over-expression of
osterix in NIH3T3 ﬁbroblasts increased osteopontin expres-
sion36 and highlights the importance of using relevant pri-
mary cell cultures where possible. Our data indicate that
for some reason the suppressive effect of IL-1b on the
Runx2/osterix pathway does not lead to reduced osteonec-
tin or osteopontin gene expression. We observed similar
inhibitory effects of IL-1b and TNFa on the gene expression
for chondrocyte (Col2a and Agc) and adipocyte (PPAR
gamma and adipisin) differentiation.
There are many situations where bone needs to be re-
generated following damage, for example, during fracture,
localized osteolysis around prosthetic implants, and joint
disease. The regenerative capabilities of MSC make them
ideal for such repair in these scenarios. However, in many
such situations where new bone needs to be formed, the
milieu is likely to contain many cytokines, including those
with proinﬂammatory activity, such as IL-1b and TNFa,
due to the concomitant damage and host response to
such damage37. Therefore it is likely that the successful re-
generation of bone will require a consideration and hence
control of this associated inﬂammatory milieu. Our ﬁndings
above support this contention by showing that the key
proinﬂammatory cytokines, IL-1b and TNFa, can have pro-
found consequences for normal bone development from
progenitor cells both at the differentiation and proliferation
levels. Therefore we suggest that much more understand-
ing of the environment surrounding osteoblast progenitors,
such as MSC, is required before successful bone regener-
ation becomes a routine reality. The development of this
isolation technique accelerates the generation of reason-
able numbers of MSC to aid in this goal. These MSC should
be useful for understanding further the molecular mecha-
nisms governing speciﬁc cytokine modulation of MSC differ-
entiation in vitro and hopefully in vivo.
Patients suffering from rheumatoid arthritis, for example,
can experience two forms of bone loss, namely that of
a generalized nature38, leading to osteoporosis, and periar-
ticular osteolysis in areas in close proximity to inﬂamed
joints39,40. Osteoclasts are commonly considered to be
mainly responsible for such reduced bone mass; however,
our work highlights the potential inhibitory effects of proin-
ﬂammatory cytokines on the anabolic actions of MSC.
741Osteoarthritis and Cartilage Vol. 17, No. 6This inhibition of MSC differentiation to osteoblasts by IL-1b
and TNFa could play a role in both types of bone loss and
may have relevance for inﬂammatory conditions, such as
rheumatoid arthritis.
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